| 5'-Deoxy-5'-Methylthioadenosine | The serum concentration of BL-1020 can be increased when it is combined with 5'-Deoxy-5'-Methylthioadenosine. | Experimental |
| Acebutolol | BL-1020 may increase the hypotensive activities of Acebutolol. | Approved |
| Alfentanil | BL-1020 may increase the hypotensive activities of Alfentanil. | Approved, Illicit |
| Alphacetylmethadol | BL-1020 may increase the hypotensive activities of Alphacetylmethadol. | Experimental, Illicit |
| Alprenolol | BL-1020 may increase the hypotensive activities of Alprenolol. | Approved, Withdrawn |
| Aluminum hydroxide | Aluminum hydroxide can cause a decrease in the absorption of BL-1020 resulting in a reduced serum concentration and potentially a decrease in efficacy. | Approved |
| Amodiaquine | The serum concentration of BL-1020 can be increased when it is combined with Amodiaquine. | Approved |
| Amoxapine | The risk or severity of adverse effects can be increased when BL-1020 is combined with Amoxapine. | Approved |
| Arotinolol | BL-1020 may increase the hypotensive activities of Arotinolol. | Approved |
| Artemether | The serum concentration of BL-1020 can be increased when it is combined with Artemether. | Approved |
| Artemisinin | The serum concentration of BL-1020 can be increased when it is combined with Artemisinin. | Investigational |
| Artesunate | The serum concentration of BL-1020 can be increased when it is combined with Artesunate. | Approved |
| Atenolol | BL-1020 may increase the hypotensive activities of Atenolol. | Approved |
| Atovaquone | The serum concentration of BL-1020 can be increased when it is combined with Atovaquone. | Approved |
| Befunolol | BL-1020 may increase the hypotensive activities of Befunolol. | Experimental |
| Betaxolol | BL-1020 may increase the hypotensive activities of Betaxolol. | Approved |
| Betulinic Acid | The serum concentration of BL-1020 can be increased when it is combined with Betulinic Acid. | Investigational |
| Bevantolol | BL-1020 may increase the hypotensive activities of Bevantolol. | Approved |
| Bezitramide | BL-1020 may increase the hypotensive activities of Bezitramide. | Experimental, Illicit, Withdrawn |
| Bismuth Subcitrate | Bismuth Subcitrate can cause a decrease in the absorption of BL-1020 resulting in a reduced serum concentration and potentially a decrease in efficacy. | Approved |
| Bisoprolol | BL-1020 may increase the hypotensive activities of Bisoprolol. | Approved |
| Bopindolol | BL-1020 may increase the hypotensive activities of Bopindolol. | Approved |
| Bucindolol | BL-1020 may increase the hypotensive activities of Bucindolol. | Investigational |
| Bufuralol | BL-1020 may increase the hypotensive activities of Bufuralol. | Experimental, Investigational |
| Bupranolol | BL-1020 may increase the hypotensive activities of Bupranolol. | Approved |
| Buprenorphine | BL-1020 may increase the hypotensive activities of Buprenorphine. | Approved, Illicit, Investigational, Vet Approved |
| Butorphanol | BL-1020 may increase the hypotensive activities of Butorphanol. | Approved, Illicit, Vet Approved |
| Calcium Carbonate | Calcium carbonate can cause a decrease in the absorption of BL-1020 resulting in a reduced serum concentration and potentially a decrease in efficacy. | Approved |
| Carfentanil | BL-1020 may increase the hypotensive activities of Carfentanil. | Illicit, Vet Approved |
| Carteolol | BL-1020 may increase the hypotensive activities of Carteolol. | Approved |
| Carvedilol | BL-1020 may increase the hypotensive activities of Carvedilol. | Approved, Investigational |
| Celiprolol | BL-1020 may increase the hypotensive activities of Celiprolol. | Approved, Investigational |
| Chloroquine | The serum concentration of BL-1020 can be increased when it is combined with Chloroquine. | Approved, Vet Approved |
| Citalopram | The risk or severity of adverse effects can be increased when BL-1020 is combined with Citalopram. | Approved |
| Clomipramine | The risk or severity of adverse effects can be increased when BL-1020 is combined with Clomipramine. | Approved, Vet Approved |
| Codeine | BL-1020 may increase the hypotensive activities of Codeine. | Approved, Illicit |
| Dapoxetine | The risk or severity of adverse effects can be increased when BL-1020 is combined with Dapoxetine. | Investigational |
| Dapsone | The serum concentration of BL-1020 can be increased when it is combined with Dapsone. | Approved, Investigational |
| Dextromoramide | BL-1020 may increase the hypotensive activities of Dextromoramide. | Experimental, Illicit |
| Dextropropoxyphene | BL-1020 may increase the hypotensive activities of Dextropropoxyphene. | Approved, Illicit, Withdrawn |
| Dezocine | BL-1020 may increase the hypotensive activities of Dezocine. | Approved |
| Dihydrocodeine | BL-1020 may increase the hypotensive activities of Dihydrocodeine. | Approved, Illicit |
| Dihydroetorphine | BL-1020 may increase the hypotensive activities of Dihydroetorphine. | Experimental, Illicit |
| Dihydromorphine | BL-1020 may increase the hypotensive activities of Dihydromorphine. | Experimental, Illicit |
| Diphenoxylate | BL-1020 may increase the hypotensive activities of Diphenoxylate. | Approved, Illicit |
| Doxycycline | The serum concentration of BL-1020 can be increased when it is combined with Doxycycline. | Approved, Investigational, Vet Approved |
| Escitalopram | The risk or severity of adverse effects can be increased when BL-1020 is combined with Escitalopram. | Approved, Investigational |
| Esmolol | BL-1020 may increase the hypotensive activities of Esmolol. | Approved |
| Ethylmorphine | BL-1020 may increase the hypotensive activities of Ethylmorphine. | Approved, Illicit |
| Etoperidone | The risk or severity of adverse effects can be increased when BL-1020 is combined with Etoperidone. | Approved |
| Etorphine | BL-1020 may increase the hypotensive activities of Etorphine. | Illicit, Vet Approved |
| Fenfluramine | The risk or severity of adverse effects can be increased when BL-1020 is combined with Fenfluramine. | Illicit, Withdrawn |
| Fentanyl | BL-1020 may increase the hypotensive activities of Fentanyl. | Approved, Illicit, Investigational, Vet Approved |
| Fluoxetine | The risk or severity of adverse effects can be increased when BL-1020 is combined with Fluoxetine. | Approved, Vet Approved |
| Fluvoxamine | The risk or severity of adverse effects can be increased when BL-1020 is combined with Fluvoxamine. | Approved, Investigational |
| Halofantrine | The serum concentration of BL-1020 can be increased when it is combined with Halofantrine. | Approved |
| Heroin | BL-1020 may increase the hypotensive activities of Heroin. | Approved, Illicit |
| Hydrocodone | BL-1020 may increase the hypotensive activities of Hydrocodone. | Approved, Illicit |
| Hydromorphone | BL-1020 may increase the hypotensive activities of Hydromorphone. | Approved, Illicit |
| Hydroxychloroquine | The serum concentration of BL-1020 can be increased when it is combined with Hydroxychloroquine. | Approved |
| Indalpine | The risk or severity of adverse effects can be increased when BL-1020 is combined with Indalpine. | Investigational, Withdrawn |
| Indenolol | BL-1020 may increase the hypotensive activities of Indenolol. | Withdrawn |
| Ketobemidone | BL-1020 may increase the hypotensive activities of Ketobemidone. | Approved |
| Labetalol | BL-1020 may increase the hypotensive activities of Labetalol. | Approved |
| Landiolol | BL-1020 may increase the hypotensive activities of Aop200704. | Investigational |
| Levobunolol | BL-1020 may increase the hypotensive activities of Levobunolol. | Approved |
| Levomethadyl Acetate | BL-1020 may increase the hypotensive activities of Levomethadyl Acetate. | Approved |
| Levomilnacipran | The risk or severity of adverse effects can be increased when BL-1020 is combined with Levomilnacipran. | Approved |
| Levorphanol | BL-1020 may increase the hypotensive activities of Levorphanol. | Approved |
| Lofentanil | BL-1020 may increase the hypotensive activities of Lofentanil. | Illicit |
| Lumefantrine | The serum concentration of BL-1020 can be increased when it is combined with Lumefantrine. | Approved |
| Magaldrate | Magaldrate can cause a decrease in the absorption of BL-1020 resulting in a reduced serum concentration and potentially a decrease in efficacy. | Withdrawn |
| Magnesium carbonate | Magnesium carbonate can cause a decrease in the absorption of BL-1020 resulting in a reduced serum concentration and potentially a decrease in efficacy. | Approved |
| Magnesium Hydroxide | Magnesium hydroxide can cause a decrease in the absorption of BL-1020 resulting in a reduced serum concentration and potentially a decrease in efficacy. | Approved |
| Magnesium oxide | Magnesium oxide can cause a decrease in the absorption of BL-1020 resulting in a reduced serum concentration and potentially a decrease in efficacy. | Approved |
| Magnesium Trisilicate | Magnesium Trisilicate can cause a decrease in the absorption of BL-1020 resulting in a reduced serum concentration and potentially a decrease in efficacy. | Approved |
| Mefloquine | The serum concentration of BL-1020 can be increased when it is combined with Mefloquine. | Approved |
| Methadone | BL-1020 may increase the hypotensive activities of Methadone. | Approved |
| Methadyl Acetate | BL-1020 may increase the hypotensive activities of Methadyl Acetate. | Approved, Illicit |
| Metipranolol | BL-1020 may increase the hypotensive activities of Metipranolol. | Approved |
| Metoprolol | BL-1020 may increase the hypotensive activities of Metoprolol. | Approved, Investigational |
| Milnacipran | The risk or severity of adverse effects can be increased when BL-1020 is combined with Milnacipran. | Approved |
| Mizoribine | The serum concentration of BL-1020 can be increased when it is combined with Mizoribine. | Investigational |
| Morphine | BL-1020 may increase the hypotensive activities of Morphine. | Approved, Investigational |
| Nadolol | BL-1020 may increase the hypotensive activities of Nadolol. | Approved |
| Nalbuphine | BL-1020 may increase the hypotensive activities of Nalbuphine. | Approved |
| Normethadone | BL-1020 may increase the hypotensive activities of Normethadone. | Approved, Illicit |
| Olanzapine | The risk or severity of adverse effects can be increased when BL-1020 is combined with Olanzapine. | Approved, Investigational |
| Opium | BL-1020 may increase the hypotensive activities of Opium. | Approved, Illicit |
| Oxprenolol | BL-1020 may increase the hypotensive activities of Oxprenolol. | Approved |
| Oxycodone | BL-1020 may increase the hypotensive activities of Oxycodone. | Approved, Illicit, Investigational |
| Oxymorphone | BL-1020 may increase the hypotensive activities of Oxymorphone. | Approved, Investigational, Vet Approved |
| Paroxetine | The risk or severity of adverse effects can be increased when BL-1020 is combined with Paroxetine. | Approved, Investigational |
| Penbutolol | BL-1020 may increase the hypotensive activities of Penbutolol. | Approved, Investigational |
| Pentazocine | BL-1020 may increase the hypotensive activities of Pentazocine. | Approved, Vet Approved |
| Pethidine | BL-1020 may increase the hypotensive activities of Pethidine. | Approved |
| Pindolol | BL-1020 may increase the hypotensive activities of Pindolol. | Approved |
| Piritramide | BL-1020 may increase the hypotensive activities of Piritramide. | Investigational |
| Practolol | BL-1020 may increase the hypotensive activities of Practolol. | Approved |
| Primaquine | The serum concentration of BL-1020 can be increased when it is combined with Primaquine. | Approved |
| Proguanil | The serum concentration of BL-1020 can be increased when it is combined with Proguanil. | Approved |
| Propranolol | BL-1020 may increase the hypotensive activities of Propranolol. | Approved, Investigational |
| Pyrimethamine | The serum concentration of BL-1020 can be increased when it is combined with Pyrimethamine. | Approved, Vet Approved |
| Pyronaridine | The serum concentration of BL-1020 can be increased when it is combined with Pyronaridine. | Investigational |
| Quinacrine | The serum concentration of BL-1020 can be increased when it is combined with Quinacrine. | Approved |
| Quinidine | The serum concentration of BL-1020 can be increased when it is combined with Quinidine. | Approved |
| Quinine | The serum concentration of BL-1020 can be increased when it is combined with Quinine. | Approved |
| Radicicol | The serum concentration of BL-1020 can be increased when it is combined with Radicicol. | Experimental |
| Remifentanil | BL-1020 may increase the hypotensive activities of Remifentanil. | Approved |
| Sertraline | The risk or severity of adverse effects can be increased when BL-1020 is combined with Sertraline. | Approved |
| Sinefungin | The serum concentration of BL-1020 can be increased when it is combined with Sinefungin. | Experimental |
| Sotalol | BL-1020 may increase the hypotensive activities of Sotalol. | Approved |
| Sufentanil | BL-1020 may increase the hypotensive activities of Sufentanil. | Approved, Investigational |
| Sulfadoxine | The serum concentration of BL-1020 can be increased when it is combined with Sulfadoxine. | Approved |
| Sulfametopyrazine | The serum concentration of BL-1020 can be increased when it is combined with Sulfametopyrazine. | Approved, Withdrawn |
| Tapentadol | BL-1020 may increase the hypotensive activities of Tapentadol. | Approved |
| Thiopental | The risk or severity of adverse effects can be increased when BL-1020 is combined with Thiopental. | Approved, Vet Approved |
| Timolol | BL-1020 may increase the hypotensive activities of Timolol. | Approved |
| Tramadol | BL-1020 may increase the hypotensive activities of Tramadol. | Approved, Investigational |
| Trazodone | The risk or severity of adverse effects can be increased when BL-1020 is combined with Trazodone. | Approved, Investigational |
| Trimethoprim | The serum concentration of BL-1020 can be increased when it is combined with Trimethoprim. | Approved, Vet Approved |
| Vilazodone | The risk or severity of adverse effects can be increased when BL-1020 is combined with Vilazodone. | Approved |
| Vortioxetine | The risk or severity of adverse effects can be increased when BL-1020 is combined with Vortioxetine. | Approved |
| Zimelidine | The risk or severity of adverse effects can be increased when BL-1020 is combined with Zimelidine. | Withdrawn |
